DURING AN INSPECTION OF YOUR FIRM I OBSERVED:

OBSERVATION 1

You used a non-pharmaceutical grade component in the formulation of a drug product.

Specifically,

Since 2017, rather than using USP grade (b)(4), your firm has been using a (b)(4) brand system which you do not routinely test to assure its production quality and contamination risks in the preparation of the following of your non-sterile drug products:

**Topical Facial Pads**
- Clear Face Pads (Salicylic Acid 2%, Sulfacetamide 5%, Clindamycin 0.5%)
- Daily Facial Peel (Pads) (Glycolic Acid 1%, Salicylic Acid 1%, Lactic Acid 3%)
- Skin Lightening Pads (Hydroquinone 4%, Kojic Acid 4%, Lactic Acid 7%)
- Ultra Complexion Pads (Glycolic Acid 10%, Salicylic Acid 5%)

**Topical Facial Solutions**
- Glycolic Acid Soln
- Retinoic Acid Soln
- Trichloroacetic Acid Soln
- Tranexamic Acid 4.8% Soln

**Topical Dental Gels and Rinse**
- BTT 12.5 Gel ((Lidocaine 12.5%, Tetracaine 12.5%, Prilocaine 3%, Phenylephrine 3%)
- Chlorhexidine 2% Gel
**Minocycline 2% Kit (in the gel)**

**Dyclonine 1% Rinse**

**Profound Gel (Lidocaine 10%, Prilocaine 10%, Tetracaine 4%)**

**TAC 20 ALT Gel (Lidocaine 20%, Tetracaine 4%, Phenylephrine 2%)**

**Enema**

- Short Chain Fatty Acid Enema
- Sod Butyrate 100 mm/L Enema

---

**DATE(S) OF INSPECTION**

10/04/2018(Thu), 10/05/2018(Fri), 10/09/2018(Tue), 10/10/2018(Wed), 10/11/2018(Thu)

---

**NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED**

Steven A. Levin, Pharmacist-In-Charge / Owner / CEO

**FIRM NAME**

Algunas Inc., dba Woodland Hills Compounding Pharmacy

**STREET ADDRESS**

20631 Ventura Blvd Ste 305

**CITY, STATE, ZIP CODE, COUNTRY**

Woodland Hills, CA 91364-2352

**TYPE ESTABLISHMENT INSPECTED**

Producer of Non-Sterile Drugs

---

**SEE REVERSE OF THIS PAGE**

Rumany C Penn, Investigator

**DATE ISSUED**

10/11/2018

---

**FORM FDA 483 (09/08)**

PREVIOUS EDITION OBSOLETE

INSPECTIONAL OBSERVATIONS